Eton Pharmaceuticals, Inc. (ETON) Form 8-K — Aug 4, 2026
Eton Pharmaceuticals appointed Danka Radosavljevic as Chief Operating Officer, effective July 31, 2026. Radosavljevic previously served as Executive Vice President of Operations, overseeing quality, product development, regulatory, supply chain, and information systems for over five years. Her new compensation package includes an annual base salary of $520,800 and a discretionary incentive bonus target of 50% of her base salary.
Key figures
- Coo base salary usd
- 520800
- Coo target bonus percent
- 50
Price after filing
1 day: +0.3%7 days: -8.2%30 days: +35.2%
Close on the filing date to close N calendar days later (from $45.83). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.